Comprehensive Cancer Center Program at Fox Chase

描述（由申请人提供）：自上次审查以来，福克斯蔡斯癌症中心在新的领导下，继续成为全国为数不多的独立综合癌症中心之一。该中心的使命是“战胜癌症，在大胆的科学发现、预防策略和富有同情心的癌症护理的合作实践中，每天汇集卓越的心灵和思想。”我们的愿景是成为全国公认的癌症研究和医学的领导者，并成为费城地区卓越的癌症中心。新的领导班子结合外部咨询委员会的建议，将CCSG的研究项目从11点整合到5点。这五个项目代表了福克斯蔡斯癌症中心的核心科学优势。在上次审查中，核准了30个CCSG共用设施和2个支助要素（议定书审查和监测系统和具体议定书研究）的供资，并提出了合并设施的建议。该提案要求对16个核心设施和2个支持要素提供部分支持。发展基金被要求在CCSG资助周期内战略性地增加这5个研究项目的临界质量。提出了征聘21至30名新调查员和替代调查员的计划。在过去的CCSG周期中，招募了40名调查员，除去我们新招募的17名，23名调查员中有19名（83%）在任命后的24个月内获得了1540万美元的同行评审资金。其中510万美元是由发展基金部分资助的调查人员筹集的。自上次提交以来，癌症研究馆按计划于2010年完工，并将为新的研究实验室提供所需的大部分空间。领导层的愿景包括通过战略基石投资增加团队科学的计划。这些机构投资旨在扩大FCCC的研究组合，包括更多的“基于团队”的资助，如计划项目资助和孢子。作为这些关键投资的直接结果，未来几年将提交几个基于团队的科学资助提案。为了满足未来增加的主要研究人员的需求，中心计划利用

DESCRIPTION (provided by applicant): The Fox Chase Cancer Center is under new leadership since the last review and continues as one of the nation's few free standing comprehensive cancer centers. The Center's mission is "To prevail over cancer, marshaling excellence of heart and mind each day in the collaborative practice of bold scientific discovery, prevention strategies, and compassionate cancer care." Our vision is to be an acknowledged national leader in cancer research and medicine and a pre-eminent cancer center in the Philadelphia area. The new leadership in conjunction with advice from External Advisory Boards has consolidated the CCSG Research Programs from 11 to 5. These five Programs represent the core scientific strengths of the Fox Chase Cancer Center. At the last review 30 CCSG Shared Facilities and 2 support elements (Protocol Review and Monitoring System and Protocol Specific Research) were approved for funding with recommendations to consolidate facilities. This proposal requests partial support for 16 core facilities and 2 support elements. Developmental Funds are requested to strategically increase critical mass for these 5 research Programs over the CCSG funding cycle. A plan is presented to recruit 21 to 30 new and replacement investigators. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer-reviewed funding within 24 months of their appointment. Of that amount $5.1 million was garnered by investigators who were partially supported by Developmental Funds. Since the last submission, the Cancer Research Pavilion was completed as planned in 2010 and will provide much of the needed space for new investigator laboratories. The Leadership's vision includes a plan to increase team-based science via strategic keystone investments. These institutional investments are intended to expand the research portfolio of FCCC to include more "team-based" grants such as Program Project Grants and SPOREs. Several team-based science grant proposals will be submitted over the next few years as a direct result of these keystone Investments. To meet the demand presented by a future increase in principal investigators, the Center plans to leverage $8 million of ARRA funds with $5.1 million of institutional investment to construct a Comparative Medical Facility (CMR). Since the last review, FCCC has implemented a formal review mechanism to evaluate and prioritize its CCSG Shared Research Resources. As a result, of this evaluation process, the number of Shared Research Resources has been streamlined.